Case Study

Zuellig Pharma (B): Putting transformation to the test

18 pages
December 2020
Reference: IMD-7-2241

Case (B) is set in January 2020 when CEO John Davison decided to step down as CEO by end of June 2020. It describes the specific actions of Zuellig Pharma’s transformation and how they resulted in more than doubling the company’s net profit between 2015 and 2019 These actions included: (1) driving operational excellence by successfully completing the ERP implementation and taking other steps to fix operational problems; (2) fostering the leadership team through selective changes and aligning it around an integrated regional strategy; (3) increasing head office control while ensuring that country operations had the autonomy needed to operate effectively; (4) resetting the relationship between the management and the board to create more alignment and trust; (5) strengthening relationships with key distribution clients; and (6) growing the solutions businesses which accounted by 2019 for over 20% of GOR and net profit. The case also describes the situation facing Zuellig Pharma as the Covid-19 pandemic began to unfold, and John Davison’s initial thoughts on related key issues facing the company.

Learning Objective
  • Crisis management in the face of the COVID-19 pandemic.
  • Resilience: Individual resilience as a leader as well as organizational and IT system resilience.
  • Succession planning
Keywords
Transformation, COVID-19
Settings
South-Eastern Asia, Singapore
Zuellig Pharma, Healthcare, Pharmaceuticals
2014 – 2020
Type
Field Research
Copyright
© 2020
Available Languages
English
Related material
Teaching note
Case clearing houses
Contact

Research Information & Knowledge Hub for additional information on IMD publications

Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics